Patents by Inventor Cynthia Y. Robinson
Cynthia Y. Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10722511Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydroccodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: October 28, 2019Date of Patent: July 28, 2020Assignee: Persion Pharmaceuticals LLCInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20200054627Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: October 28, 2019Publication date: February 20, 2020Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 10456393Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: July 23, 2018Date of Patent: October 29, 2019Assignee: Persion Pharmaceuticals LLCInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 10322120Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: October 24, 2014Date of Patent: June 18, 2019Assignee: Persion Pharmaceuticals LLCInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20180338966Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: July 23, 2018Publication date: November 29, 2018Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 10028946Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: April 3, 2017Date of Patent: July 24, 2018Assignee: Pernix Ireland Pain Designated Activity CompanyInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20170202831Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9610286Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: November 1, 2016Date of Patent: April 4, 2017Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20170042885Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: November 1, 2016Publication date: February 16, 2017Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9522147Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: August 22, 2016Date of Patent: December 20, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160354365Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: August 22, 2016Publication date: December 8, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160263107Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160256455Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 13, 2016Publication date: September 8, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9433619Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 13, 2016Date of Patent: September 6, 2016Assignee: Pemix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Publication number: 20160250207Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: ApplicationFiled: May 13, 2016Publication date: September 1, 2016Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9421200Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 13, 2016Date of Patent: August 23, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9421201Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: May 20, 2016Date of Patent: August 23, 2016Assignee: Pemis Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9339499Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 17, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9333201Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 10, 2016Assignee: Pernix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
-
Patent number: 9326982Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.Type: GrantFiled: December 22, 2015Date of Patent: May 3, 2016Assignee: Pemix Ireland Pain LimitedInventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson